|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Hypertriglyceridemia |
|
Hypercholesterolemia |
|
Hyperlipidemia |
| |
|
|
SIDE EFFECTS:
|
|
Influenza syndrome |
|
infections |
|
pruritus |
|
skin rash and/or urticaria |
|
Agranulocytosis |
|
alveolitis, allergic |
|
cholecystitis |
|
cholelithiasis |
|
eczema |
|
hepatotoxicity |
|
musculoskeletal symptoms, such as myalgia |
|
myasthenia |
|
myositis |
|
rhabdomyolysis |
|
pancreatitis |
|
thrombocytopenia |
|
Dizziness |
|
eye irritation |
|
gastrointestinal symptoms, such as belching |
|
constipation |
|
flatulence |
|
libido, decreased |
|
photosensitivity |
|
rhinitis |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Renal function impairment, moderate |
|
|
ADULT DOSE:
|
|
Antihyperlipidemic-
Oral, initially, 67 mg per day, depending on the physician's assessment of the patient's risk for pancreatitis .
Dosage should be individualized according to patient response, and should be increased sequentially, if necessary, following repeat serum triglyceride estimations at 4- to 8-week intervals .
Fenofibrate should be discontinued in patients who do not have an adequate response after two months of treatment with the maximum recommended dose (201 mg per day) .
In patients with impaired renal function, treatment should be initiated at a dose of 67 mg per day and increased only after the effects of fenofibrate on renal function and triglyceride concentrations have been evaluated . |
|
MAXIMUM ADULT DOSE:
|
|
201 mg per day .
|
|
PEDIATRIC DOSE:
|
|
Safety and efficacy have not been established .
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
Antihyperlipidemic-
Oral, initially, 67 mg per day .
See Usual adult dose . |
|
|
|
|
|